Inside the Strategy Room cover image

159. Voices of CEO Excellence: Merck’s Ken Frazier. Episode 1

Inside the Strategy Room

00:00

The Importance of R&D in Pharmaceutical CEOs

A Wall Street analyst report said pharmaceutical CEOs should stop investing in R&D and invest in non-farma assets. Merck had five-year earnings guidance, which only two of those five years had elapsed when I took over. "I felt very strongly that if Merck was going to be an R&D focus company, this was the moment of truth for us," he says.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app